<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01334645</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0092</org_study_id>
    <secondary_id>2010-A01186-33</secondary_id>
    <nct_id>NCT01334645</nct_id>
  </id_info>
  <brief_title>Copeptin and Acute Coronary Syndrome Without ST-segment Elevation</brief_title>
  <official_title>Diagnostic Value of Copeptin Assay for Acute Coronary Syndrome Without ST-segment Elevation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association des Médecins des Urgences de Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BRAHMS Biomarkers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital Henri Mondor, Aurillac, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the combination of copeptine and troponin&#xD;
      adds diagnosis information to that provided by troponin alone or the combination of troponin&#xD;
      and myoglobin.&#xD;
&#xD;
      Hypothesis : If the values of troponin and copeptin are not elevated, diagnosis of acute&#xD;
      myocardial infarction can be ruled out without prolonged monitoring and serial blood&#xD;
      sampling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients older than 18 years with pain suggestive of Acute Coronary Syndrome, with onset&#xD;
      within the last 12 hours, presenting to the Emergency Department of the University Hospital&#xD;
      Gabriel Montpied (Clermont-Ferrand, France) and the General Hospital Henri Mondor (Aurillac,&#xD;
      France) are enrolled.&#xD;
&#xD;
      Upon admission to the hospital, all patient underwent an initial clinical assessment,&#xD;
      including medical history, temperature, respiratory rate, cardiac frequency, blood pressure,&#xD;
      pulse oxymetry, 18-lead ECG, chest X-ray and screening blood test including C reactive&#xD;
      protein, natremia, Troponine T, myoglobin, creatin kinase and copeptine.&#xD;
&#xD;
      Patients with hyponatremia &lt; 135 mmol/L or troponin &gt; 1 μg/L are released study.&#xD;
&#xD;
      Blood sampling are taken for Troponine T, myoglobin, creatin kinase and copeptine analysis&#xD;
      and 18-lead ECG was performed after 2, 4, 6 and 12 h.&#xD;
&#xD;
      Copeptin and myoglobin are measured at the end of the patients inclusion, after to be&#xD;
      centrifugrd end frozen at -80°C at each time point.&#xD;
&#xD;
      The treatment of patients is not modified by the study. At 90 days, clinicals and&#xD;
      paraclinicals events are collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Copeptin value</measure>
    <time_frame>at day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Troponin, Myoglobin and Creatin Kinase values. Clinicals and paraclinicals events .</measure>
    <time_frame>at 90 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">134</enrollment>
  <condition>Chest Pain</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Copeptin</intervention_name>
    <description>Patients with hyponatremia &lt; 135 mmol/L or troponin &gt; 1 μg/L are released study.&#xD;
Blood sampling are taken for Troponine T, myoglobin, creatin kinase and copeptine analysis and 18-lead ECG was performed after 2, 4, 6 and 12 h.&#xD;
Copeptin and myoglobin are measured at the end of the patients inclusion, after to be centrifugrd end frozen at -80°C at each time point.&#xD;
The treatment of patients is not modified by the study. At 90 days, clinicals and paraclinicals events are collected</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chest pain suggestive of Acute Coronary Syndrome&#xD;
&#xD;
          -  Chest pain with onset within the last 12 h&#xD;
&#xD;
          -  Patients older than 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ST-Elevation Myocardial infarction&#xD;
&#xD;
          -  Legal incapacity&#xD;
&#xD;
          -  Sepsis&#xD;
&#xD;
          -  Hyponatremia &lt; 135 mmol/L&#xD;
&#xD;
          -  Shock&#xD;
&#xD;
          -  Lung neoplasms&#xD;
&#xD;
          -  life expectancy of less than 6 months&#xD;
&#xD;
          -  Refuse to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan DUCHENNE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>April 11, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2011</study_first_posted>
  <last_update_submitted>May 28, 2013</last_update_submitted>
  <last_update_submitted_qc>May 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Copeptin</keyword>
  <keyword>Troponin</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Chest pain</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Unstable Angina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Insipidus</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Chest Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

